|Bid||41.01 x 800|
|Ask||41.48 x 1800|
|Day's Range||41.00 - 42.72|
|52 Week Range||31.56 - 43.66|
|Beta (3Y Monthly)||0.70|
|PE Ratio (TTM)||41.59|
|Earnings Date||Oct 22, 2019 - Oct 28, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||48.14|
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
MARLBOROUGH, Mass. , Aug. 20, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2019 Wells Fargo Securities Healthcare Conference on Thursday, September ...
MARLBOROUGH, Mass., Aug. 19, 2019 /PRNewswire/ -- Boston Scientific Corporation (BSX) announced the U.S. Food and Drug Administration (FDA) approval of its ImageReady™ MRI labeling for the Vercise Gevia™ Deep Brain Stimulation (DBS) System to be used in a full-body magnetic resonance imaging (MRI) environment.1 This system, with the Vercise Cartesia™ Directional Lead, is designed to treat the symptoms of Parkinson's Disease (PD) by delivering precisely targeted electrical stimulation in the brain to provide optimal symptom relief and better control of unwanted side effects.
MARLBOROUGH, Mass., Aug. 19, 2019 /PRNewswire/ -- Boston Scientific Corporation (BSX) today announced the completion of its acquisition of BTG plc. (BTG.L) pursuant to the previously announced scheme of arrangement. BTG has three key businesses, the largest of which is its highly-differentiated Interventional Medicine portfolio that encompasses interventional oncology therapeutic technologies for patients with liver and kidney cancers, as well as a vascular portfolio for treatment of deep vein thrombosis, pulmonary embolism, deep venous obstruction and superficial venous disease. "The addition of the BTG Interventional Medicine portfolio reinforces our category leadership strategy and enables us to offer best-in-class technologies, unparalleled clinical evidence and a strengthened commercial infrastructure to support physicians treating some of the most challenging diseases impacting patient health around the world," said Mike Mahoney, chairman and chief executive officer, Boston Scientific.
Teledyne Technologies, Netgear, Boston Scientific, Medtronic and Becton Dickinson highlighted as Zacks Bull and Bear of the Day
On its advisory list, the FDA suggests that doctors should point out the risks and benefits of all available PAD treatment options to their patients.
This study outcome is expected to be a major stride forward in Cardiovascular Systems' (CSII) endeavor to offer treatment to patients of multi-level peripheral artery disease (PAD).
Today, we'll introduce the concept of the P/E ratio for those who are learning about investing. To keep it practical...
Cerevel announced Wednesday that Bain Capital principal Orly Mishan has moved from a space on the company's board of directors to become its new chief business officer.
Within MedSurg, Boston Scientific (BSX) is on track for the year-end launch of Exalt-D Single-Use Duodenoscope, which is used in ERCP procedures.
Here we discuss four medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
Mayo Clinic and Boston Scientific Corp. on Monday will announce the formation of Motion Medical, a medical-technology accelerator housed in Rochester's new Destination Medical Center development.
Today we'll evaluate Boston Scientific Corporation (NYSE:BSX) to determine whether it could have potential as an...
MARLBOROUGH, Mass. , July 25, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 39 th Annual Canaccord Genuity Growth Conference on Thursday, August 8, 2019 in Boston ...
Boston Scientific and Thermo Fisher Scientific stocks tripped Wednesday after the medtech companies beat second-quarter earnings forecasts, but reported roughly in-line revenue.